Table of Contents. Elsevier Clinical Solutions Drug Pricing PRICING POLICIES PRICING POLICIES... 1 REPORTED PRICES... 1 CALCULATED PRICE TYPES...

Similar documents
An Update on Acquisition Cost Based Reimbursement Models. Jerry Brehany, PharmD, PA-C, JD AVP Pharmacy Services

Drug Price Types and Options for a Future Standard

Iowa Medicaid Enterprise Average Actual Acquisition Cost Reimbursement Frequently Asked Questions

Recommendations for Medicaid Pharmacy Reimbursement for the State of Louisiana

Overview of Drug Pricing for Public Programs

Prescription Drug Pricing

B. ii. The provider's usual and customary charge to the general public; or

340B Drug Discount Program Overview and Emerging Issues

The Impact of Recent Medicare and Medicaid Cuts on Patients Access to Independent Community Pharmacies

SMAC represents the ceiling price that the program is going to reimburse for generics and is determined by:

Will the ASP data submitted to CMS be releasable to the public?

Impact of Health Reform on Prescription Drugs

Prescription-drug expenditures are one of

Reimbursement Update: Market Changes and Proposed AMP Regulations

Hot Topics in Medicaid

CONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE

MEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE

MEDICARE PART D PRESCRIPTION DRUG COVERAGE 2016

TEXAS VENDOR DRUG PROGRAM PHARMACY PROVIDER PROCEDURE MANUAL

OFFICE OF INSPECTOR GENERAL

STATE 340B MEDICAID BILLING BEST PRACTICES

CONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE

August 7, Dear Mr. Helgerson:

COMPARING PHARMACY REIMBURSEMENT: MEDICARE PART D TO MEDICAID

Predictive Acquisition

E-ALERT Health Care HEALTH CARE REFORM: MEDICAID PRESCRIPTION DRUG REIMBURSEMENT. Executive Summary

Prescription drug costs continue to rise at

Reimbursement for Physician- Administered Drugs:

Medicaid Covered Outpatient Prescription Drug Reimbursement Information by State. Quarter Ending September 2015

Data Analysis Brief. Price Negotiation for the Medicare Drug Program: It is Time to Lower Costs for Seniors

HEALTH CENTER REIMBURSEMENT FOR PRESCRIPTION DRUGS: MEDICAID PPS AND SECTION 340B DRUG PRICING CONSIDERATIONS

National Centre for Pharmacoeconomics. Guidelines for Inclusion of Drug Costs in Pharmacoeconomic Evaluations

TRADE AGREEMENTS ACT LIMITATIONS ON PROCUREMENT OF PHARMACEUTICALS AND POTENTIAL VA SOLUTIONS

Economic Report on Retail, Mail, and Specialty Pharmacies

340B Drug Pricing Program

WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

THE COST OF EMERGENCY CONTRACEPTION: Results from a Nationwide Survey

C. Covered 340B drugs, as found in section 1927 (k)(2) of the Social Security Act, include the following outpatient drugs:

Our pharmacy, medical/surgical and capital equipment catalogs with over 550,000 line items.

The PHS 340B Drug Pricing Program

The Federal 340B Drug Discount Program: A Primer

Prescription Drug Program

Settlement Impact on AWP Drug Pricing for Payors, Pharmacies, PBMs, and Consumers

(I) The following prescribed drugs are included: (a) drugs, which require a prescription, except for those drugs specifically excluded;

Closing the Coverage Gap

2014 Prescription Drug Schedule Humana Medicare Employer Plan

Pharmacy Benefit Managers: What we do

MEDICARE PRESCRIPTION DRUG PLANS: INFORMATION FOR CONSUMERS

Introduction. Plan sponsors include employers, unions, trust funds, associations and government agencies, and are also referred to as payors.

Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B,

Health Care Reform Legislation and You

The Unintended Consequences of Restrictions on the Use of Maximum Allowable Cost Programs ( MACs ) for Pharmacy Reimbursement

Medicare Part D. MMA establishes a standard Part D drug benefit, which consists of four components or phases.

340B DISCOUNT DRUG PROGRAM OVERVIEW

Connecticut Department of Social Services Medical Assistance Program Provider Bulletin. PB June 2008

SECTION 12 - REIMBURSEMENT METHODOLOGY

Blue Cross Blue Shield of Michigan

Survey of Dispensing Costs of Pharmaceuticals in the State of Oregon

The Affordable Care Act Impact to those with Chronic conditions in Washington State

Economic Report on Retail, Mail, and Specialty Pharmacies

2012 Summary of Benefits

340B Drug Pricing Program January 15, 2015

PRESCRIPTION DRUGS. Comparison of DOD, Medicaid, and Medicare Part D Retail Reimbursement Prices

Effectively Managing a Medicaid Pharmacy Benefit Program

Medicare Coverage Gap Discount Program Dispute Resolution

Welcome to the LILETTA Patient Savings Program

May 12 14, 2015 Miami, Florida

GAO FEDERAL EMPLOYEES HEALTH BENEFITS. Effects of Using Pharmacy Benefit Managers on Health Plans, Enrollees, and Pharmacies

PRICE REPORTING COMPLIANCE: BEST PRACTICES IN REPORTING MEDICAID DRUG REBATE PROGRAM AND PART B ASP DATA. November 16, 2004


ASHP Regulatory Alert

The Impact of Medicare Part D on the Percent Gross Margin Earned by Texas Independent Pharmacies for Dual Eligible Beneficiary Claims

Pharmaceutical Marketplace Dynamics Expenditures, Distribution, Coverage, Pricing

Medicare Part D Amounts Will Increase in 2016

When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC

Coding Systems. Understanding NDC and HCPCS. December 2014

The Basics of Pharmacy Benefits Management (PBM) 2009

Pfizer Struggles to Maintain Lipitor Sales Will Aggressive Discounting and Rebating Pay Off?

Maximizing the 340B Drug Discount Program: A Webinar for Finance Executives in 340B Hospitals Webinar

10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR

Prepared By: The Professional Staff of the Committee on Banking and Insurance REVISED:

340B Integrity Audit: Is Your Hospital Ready for a HRSA Audit? February 4, 2013

4/3/2015 WHAT IS 340B? DISCLOSURE. No conflicts of interest to disclose

Connecticut Department of Social Services Medical Assistance Program Provider Bulletin. PB June 2008

An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit

Session 1: Core Pharmaceutical Datasets Retail and Non Retail Laura Jenkins Jirele

PBM Revenue Generation Secrets HEALTHCARE ANALYTICS

COMPOUNDED DRUGS. TRICARE s Payment Practices Should Be More Consistent with Regulations

Military Fee Assistance Payment Policies and Procedures

Health Reimbursement Arrangement (HRA).

Billing with National Drug Codes (NDCs) Frequently Asked Questions

Pharmacy Benefit Managers

Affordable Care Act (ACA) Health Insurance Exchanges and Medicaid Expansion

Strategic Issues in Managing the Specialty Pharmacy Benefit. Tim Watson, PharmD, MBA

Medicare Part D Prescription Drug Coverage

LILETTA Patient Savings Program

340B Drug Pricing Program: Overview and Recent Developments

The Impact of Reinsurance on Group Health Plans

Medicare Part D Prescription Drug Coverage

Federal 340B Drug Pricing Program

Transcription:

PRICING POLICIES

PRICING POLICIES Table of Contents PRICING POLICIES... 1 REPORTED PRICES... 1 CALCULATED PRICE TYPES... 3 Revision: 28 June 2016 Copyright 2016 Elsevier. All rights reserved. Page i

Pricing Policies Reported Prices Elsevier offers several price types as they are directly reported from the product marketing firms, government agencies or private entities. These include: Average Wholesale Price (AWP), Wholesale Acquisition Cost (WAC), Direct Price (DP), Federal Supply Schedule (FSS), CMS Federal Upper Limit (CMS-FUL), National Average Drug Acquisition Cost (NADAC), Maximum Allowable Cost (MAC), Average Acquisition Cost (AAC), Affordable Care Act- Federal Upper Limit (ACA-FUL), and Predictive Acquisition Cost (PAC). 1) Average Wholesale Price (AWP): a) AWP is supplied for all packages in which the marketing firm reports a suggested average wholesale price. b) The AWP reported by Elsevier is not intended to represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. c) Elsevier does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting AWP. AWP will change only as a function of a reported price change by the marketing firm. As Elsevier does not require pricing for a product to be listed, it is acceptable for the AWP field to be zero. 2) Wholesale Acquisition Cost (WAC): a) WAC is defined in the Medicare Prescription Drug, Improvement and Modernization Act of 2003 as follows: The term Wholesale Acquisition Cost means, with respect to a drug or biological, the manufacturer s list price for the drug or biological to wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates or reductions in price, as reported in wholesale price guides or other publications of drug or biological pricing data. b) The WAC price is populated for those manufacturers that report a WAC price. Elsevier publishes the WAC as it is directly reported to Elsevier by the product s marketing firm. 3) Direct Price: a) Direct price is defined as the list price for a drug or biological to non-wholesaler customers, not including prompt pay or other discounts, rebates or reductions in price. b) Direct price is populated for those manufacturers that sell direct and report a Direct Price for their products. Elsevier publishes the Direct Price as it is directly reported to Elsevier by the product s marketing firm. 4) Federal Supply Schedule (FSS): Revision: 28 June 2016 Copyright 2016 Elsevier. All rights reserved. Page 1

a) The US Department of Veterans Affairs publishes FSS and FSS Big 4 pricing for pharmaceutical products. b) FSS pricing is the multiple-award, multi-year federal contract which satisfies all federal contract laws and regulations, based on vendors business with commercial customers. c) FSS Big 4 pricing is only available to VA, Department of Defense, Public Health Service (Indian Health Service), and U.S. Coast guard customers. While FSS dual prices are negotiated for Other Government Agencies that comprise the remaining authorized users of the FSS program. Elsevier publishes the FSS and FSS Big 4 prices as posted on the US Department of Veterans Affairs web site. 5) CMS Federal Upper Limit Price (CMS- FUL): Elsevier publishes the CMS Federal Upper Limit prices as they are reported by the Centers for Medicare and Medicaid Services. Note: CMS Federal Upper Limit Price (CMS- FUL) was EndDated as of 31 March 2016. 6) National Average Drug Acquisition Cost (NADAC): The NADAC, created by the Centers for Medicare & Medicaid Services, is a survey-based price type that is based on a monthly voluntary survey of randomly selected pharmacies nationwide. The NADAC file is updated on a weekly basis and each month a new survey file is posted to reflect findings from the previous month s survey results. Elsevier publishes both the weekly file and monthly file in separate price fields. 7) Maximum Allowable Cost (MAC): The state-defined reimbursement limit for multi-source drugs. Each state sets its own MAC program, which can include more drugs than are covered under FUL. Not all states publish a MAC. Elsevier publishes the MAC as reported by the each state. 8) Average Acquisition Cost (AAC): The average cost at which pharmacies within a particular state purchase a drug. The cost is defined and calculated by the applicable state Medicaid program. Not all states calculate an AAC. Elsevier publishes the AAC as reported by the each state. 9) Affordable Care Act- Federal Upper Limit (ACA-FUL): Elsevier publishes the CMS Federal Upper Limit prices as they are reported by the Centers for Medicare and Medicaid Services. (ACA-FUL) is populated at the Specific Drug Product (SDP) Level. 10) Predictive Acquisition Cost (PAC): Revision: 28 June 2016 Copyright 2016 Elsevier. All rights reserved. Page 2

A new drug price type that more accurately tracks true acquisition cost. PAC is published by Glass Box Analytics. Elsevier publishes the PAC as reported by Glass Box Analytics and is the exclusive distributer of the PAC price type. Calculated Price Types In addition to publishing the aforementioned reported price types, Elsevier publishes three (3) calculated price types: Calculated AWP (C-AWP), Calculated AWP 1.20 (C-AWP 1.20), and Calculated CMS Federal Upper Limit Price (C-CMS-FUL). 1) Calculated Average Wholesale Price (C-AWP): a) For companies not suggesting an AWP, a mark-up of 25% is applied to the reported WAC. b) If no WAC is reported, then a 25% mark-up is applied to the reported Direct Price (DP). c) If a marketing firm does not report either a WAC or DP, then there will be no Calculated AWP price applied to the package. 2) Calculated Average Wholesale Price 1.20 (C-AWP 1.20): a) For companies not suggesting an AWP, a mark-up of 20% is applied to the reported WAC. b) If no WAC is reported, then a 20% mark-up is applied to the reported Direct Price (DP). c) If a marketing firm does not report either a WAC or DP, then there will be no Calculated AWP price applied to the package. If companies report a suggested Average Wholesale Price, a Calculated Average Wholesale Price is not applied. Therefore, there will either be a reported AWP, or C-AWP and C-AWP 1.20. 3) Calculated CMS Federal Upper Limit Price (C-CMS-FUL): On the last day of each calendar month at 11:30 PM EST, Elsevier calculates a proposed CMS FUL Price, and applies that price to all package sizes of each product that meet the same criteria used by CMS to create their published FUL, without regard to the use of the most common package size: Using a unique combination of ingredient(s), strength(s), Dosage Form and Route of Administration as the marker for a representative product, Elsevier applies the following criteria to create a Calculated CMS-FUL: 1) There must be three (3) actively marketed products by different firms at the time of calculation. 2) The unit price is calculated for both the reported WAC and/or DP price types, regardless of unit quantity per package. 3) A markup of 150% is applied to the lowest WAC or DP unit price for the unique representative product, and is considered the Calculated CMS FUL (C-CMS-FUL). Revision: 28 June 2016 Copyright 2016 Elsevier. All rights reserved. Page 3

4) A price record for the Calculated CMS FUL is assigned to all package sizes of all actively marketed versions of the representative product. The previous Calculated CMS FUL record s EndDate is set to the last day of the month, thereby making it an inactive price. Revision: 28 June 2016 Copyright 2016 Elsevier. All rights reserved. Page 4